Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of Remdesivir-HU in moderate and severe COVID-19
2020-004928-42Phase 3Completed
- Sponsor
- Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of remdesivir in coronavirus disease 2019 (COVID-19), sponsored by Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium. Primary endpoint: Treatment-emergent adverse events of special interest. Started Oct 2020; status: completed.
02
Drugs
remdesivir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004928-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004928-42.